AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial

AstraZeneca and Amgen have released topline data from a Phase III trial of its inflammatory therapy, Tezspire (tezepelumab) in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).